We treated four GCB DLBCL (FARAGE, OCI‐LY‐19, SU‐DHL‐8, and WSU‐DLCL2), one MCL (REC1), and one CLL (MEC1) cell lines with LRRK2‐IN‐1 as single agent (Figure 4A). Here, LRRK2 is linked to B-cell chronic lymphocytic leukemia.